Asymchem plans additional investment in Dunhua manufacturing facility
Asymchem Laboratories has announced its plans to invest another $12m in its Dunhua manufacturing facility to increase downstream capacity.
The plant manufactures raw materials, including chemicals and intermediates used in pharmaceutical manufacturing, InPharma reported.
The new facility will accommodate high-volume processes and back-end integration for starting materials or intermediates that will then be further processed in Asymchem's Tianjin and Fuxin facilities.
The new facility will free up capacity at other Asymchem's sites in China, allowing its manufacturing resources to be used in a more efficient manner, the company said.
Asymchem CEO Hao Hong said Dunhua operational will support existing and new manufacturing contracts, and will help the company expand in the global custom development and manufacturing markets.
Related Insight
Suppliers Directory
BioBuffer Solutions - Biopharm/Biotech Buffers and Reagents
BioBuffer Solutions is a manufacturer of biological buffers and laboratory reagents intended for use in the biopharm and biotech markets. The staff at BioBuffer Solutions has over 15 years of experience in the manufacturing and quality management of these buffers and reagents. We offer fully traceable custom buffers, reagents and solutions.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Roquette Pharma - Manufacturer of Pharmaceutical Excipients and Actives
Roquette is a global manufacturer of pharmaceutical excipients and actives, having been a major supplier to the pharmaceutical industry for more than thirty years and contributing through the reliability of its products to many successful formulations.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
InnoCore Technologies BV – Injectable and Implantable Drug Delivery Products and Drug-Eluting Medical Devices
InnoCore is a drug delivery company providing controlled release systems for the pharmaceutical and medical device industry.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Unither - Sterile, Unit Close Preparations
Unither Pharmaceuticals is the world's leading contract manufacturer of sterile, unit close preparations.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Fine & Speciality Chemicals Intelligence
SynBiosys™ Drug Eluting Stent Coating
Published by InnoCore Technologies BV
Production & Manufacturing > Fine & Speciality Chemicals > White Papers
Learn More About DSM
Published by DSM
Production & Manufacturing > Fine & Speciality Chemicals > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.